Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracisLovastatin protects against experimental plague in miceChallenges of antibacterial discoveryLevofloxacin cures experimental pneumonic plague in African green monkeys.Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelProtection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacinImpact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.A Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes.Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
P2860
Q26771850-68F323B6-3614-43C2-B21C-9C9A6D3F51C1Q28384759-D15A8BE7-BEA2-412B-9E1A-6A5DCE33B88DQ28474160-D63456DF-C12F-4FBF-9E8B-1C3D0F58DF3EQ33793074-3FA973D4-3836-4365-8BCD-FE7129D539F2Q33828874-09448D45-10A8-432A-B3F7-53C4F54253B3Q34298994-2E67AA9C-4DDE-4E93-81BF-1339D8762DE4Q34368520-EED74DA7-F410-4EA1-9A3C-4289198D74CEQ34529303-EC8C6867-9AD6-4B9D-9576-6304B29C4C03Q35005186-5A3B8394-5A91-4D20-A092-91495F161FC4Q35363899-35602A83-D4D4-47E4-85D9-60FAAF710E98Q35806278-CCD9B5BF-1100-4B56-B9EB-D5A0A10AAA0AQ36913976-DA08BA42-1FC2-4331-90ED-2210DDD43B52Q37145022-8D6EBFCD-91DA-4629-9DAE-0768CB2ED656Q37409976-8550DE49-0AB9-48F1-A8A3-B66AF0463DFDQ42237788-88F4E67E-8AD7-4C7C-85CC-EB97D384803C
P2860
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Impact of resistance selection ...... vofloxacin for plague therapy.
@ast
Impact of resistance selection ...... vofloxacin for plague therapy.
@en
type
label
Impact of resistance selection ...... vofloxacin for plague therapy.
@ast
Impact of resistance selection ...... vofloxacin for plague therapy.
@en
prefLabel
Impact of resistance selection ...... vofloxacin for plague therapy.
@ast
Impact of resistance selection ...... vofloxacin for plague therapy.
@en
P2093
P2860
P356
P1476
Impact of resistance selection ...... vofloxacin for plague therapy.
@en
P2093
Arnold Louie
George L Drusano
Mark R Deziel
Weiguo Liu
P2860
P304
P356
10.1128/AAC.00073-07
P407
P577
2007-05-21T00:00:00Z